” The profoundly important … Schizophrenia has undergone a transition from being viewed as a psychologically caused familial more information disorder to being

understood as a complex genetic disorder in which multiple genes contribute in an additive or perhaps interactive, oligogenic fashion to yield a total risk or a vulnerability to developing the disorder. Interestingly, in a sort of figure ground reversal, the initial enthusiasm of seeing schizophrenia as an easy-to-dissect genetic disorder Inhibitors,research,lifescience,medical was eventually replaced by the understanding that schizophrenia is about 50% genetically mediated7 with the remainder of disease liability probably attributable to nongenetic factors.8-10 The evolution of our understanding of schizophrenia as a family of disorders that are mediated by complex genetic vulnerability and gene-environment interactions parallel the advances seen in the conceptualization

Inhibitors,research,lifescience,medical of many other medical disorders, such as colon cancer, hemochromatosis, diabetes, and hypertension.7 Interestingly, all of these disorders are felt to be attributable to a complex interplay of vulnerability genes that predispose an individual to developing a disease and nongenetic “second hits” that precipitate the disorders (Figure 2). If the genetic loading or risk is strong enough (for example, as in multiplex families), even minor precipitants may result in the development Inhibitors,research,lifescience,medical of the disorder. On the other hand, if the cumulative genetic risk of developing schizophrenia is relatively mild, it may Inhibitors,research,lifescience,medical take a more profound nongenetic second hit (Figure 2) to start the cascade of events that ultimately result in the full expression of the disease. Figure 2. The vulnerability-stress 2-hit model of schizophrenia.

“High” levels of vulnerability interacting with high levels of stressors (eg, neonatal hypoxema or adolescent stimulant abuse) may “evoke” the emergence of schizophrenia. Inhibitors,research,lifescience,medical … There is an interesting “natural history” in the schizophrenia literature itself. First, there were descriptions of the disorder and associated “deficits” in many domains. Second, studies of clinically unaffected relatives of schizophrenia GSK-3 patients pointed the way to an Bortezomib structure intermediate state of impairment (called endophenotypes) in each of these independently studied domains. These types of deficits occur across multiple domains such as metabolic functioning (catechol-O-methyltransferase [COMT]), neurophysiology (P50 event-related potential [ERP] suppression), and neurocognition (vigilance, as measured by the continuous performance task [CPT], and verbal memory, as measured by the California Verbal Learning Test [CVLT]).7 The “intermediate” or partial deficits found in clinically unaffected relatives of schizophrenia patients gave investigators the insight crucial for the development and understanding of “endophenotypes” or intermediate phenotypes.